NCL Corporation Ltd. Announces Closing of $850,000,000 of Senior Notes

MIAMI, Dec. 18, 2020 (GLOBE NEWSWIRE) — NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), announced today that it has closed its previously announced private offering of $850 million aggregate principal amount of its 5.875% senior notes due 2026 (the “Notes”). NCLC expects to use the net proceeds from the offering for general corporate purposes. The Notes will be guaranteed by certain of NCLC’s subsidiaries on a senior unsecured basis.

The Notes were offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States, only to non-U.S. investors pursuant to Regulation S. The Notes will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this press release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including, without limitation, those regarding our business strategy, financial position, results of operations, plans, prospects, actions taken or strategies being considered with respect to our liquidity position, valuation and appraisals of our assets and objectives of management for future operations (including those regarding expected fleet additions, our voluntary suspension, our ability to weather the impacts of the COVID-19 pandemic, our expectations regarding the resumption of cruise voyages and the timing for such resumption of cruise voyages, the implementation of and effectiveness of our health and safety protocols, operational position, demand for voyages, financing opportunities and extensions, and future cost mitigation and cash conservation efforts and efforts to reduce operating expenses and capital expenditures) are forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words. Forward-looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these risks, uncertainties and other factors include, but are not limited to, the impact of:

  • the spread of epidemics, pandemics and viral outbreaks and specifically, the COVID-19 pandemic, including its effect on the ability or desire of people to travel (including on cruises), which are expected to continue to adversely impact our results, operations, outlook, plans, goals, growth, reputation, cash flows, liquidity, demand for voyages and share price;
  • our ability to comply with the U.S. Centers for Disease Control and Prevention (“CDC”) Framework for Conditional Sailing Order and to otherwise develop enhanced health and safety protocols to adapt to the current pandemic environment’s unique challenges once operations resume and to otherwise safely resume our operations when conditions allow;
  • coordination and cooperation with the CDC, the federal government and global public health authorities to take precautions to protect the health, safety and security of guests, crew and the communities visited and the implementation of any such precautions;
  • our ability to work with lenders and others or otherwise pursue options to defer, renegotiate or refinance our existing debt profile, near-term debt amortization, newbuild related payments and other obligations and to work with credit card processors to satisfy current or potential future demands for collateral on cash advanced from customers relating to future cruises;
  • our potential future need for additional financing, which may not be available on favorable terms, or at all, and may be dilutive to existing shareholders;
  • our indebtedness and restrictions in the agreements governing our indebtedness that require us to maintain minimum levels of liquidity and otherwise limit our flexibility in operating our business, including the significant portion of assets that are collateral under these agreements;
  • the accuracy of any appraisals of our assets as a result of the impact of COVID-19 or otherwise;
  • our success in reducing operating expenses and capital expenditures and the impact of any such reductions;
  • our guests’ election to take cash refunds in lieu of future cruise credits or the continuation of any trends relating to such election;
  • trends in, or changes to, future bookings and our ability to take future reservations and receive deposits related thereto;
  • the unavailability of ports of call;
  • future increases in the price of, or major changes or reduction in, commercial airline services;
  • adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events;
  • adverse incidents involving cruise ships;
  • adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence;
  • any further impairment of our trademarks, trade names or goodwill;
  • breaches in data security or other disturbances to our information technology and other networks or our actual or perceived failure to comply with requirements regarding data privacy and protection;
  • changes in fuel prices and the type of fuel we are permitted to use and/or other cruise operating costs;
  • mechanical malfunctions and repairs, delays in our shipbuilding program, maintenance and refurbishments and the consolidation of qualified shipyard facilities;
  • the risks and increased costs associated with operating internationally;
  • fluctuations in foreign currency exchange rates;
  • overcapacity in key markets or globally;
  • our expansion into and investments in new markets;
  • our inability to obtain adequate insurance coverage;
  • pending or threatened litigation, investigations and enforcement actions;
  • volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees;
  • our inability to recruit or retain qualified personnel or the loss of key personnel or employee relations issues;
  • our reliance on third parties to provide hotel management services for certain ships and certain other services;
  • our inability to keep pace with developments in technology;
  • changes involving the tax and environmental regulatory regimes in which we operate; and
  • other factors set forth under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 27, 2020, as updated by our Current Report on Form 8-K filed on July 8, 2020, and our Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020.

Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 pandemic. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown.

The above examples are not exhaustive and new risks emerge from time to time. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made.

We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

Investor Relations & Media Contact

Andrea DeMarco
(305) 468-2339
[email protected]

Jessica John
(786) 913-2902



Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired non-executive officer employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “Effective Date”).

The 2020 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pacific Biosciences as an inducement material to such individual’s entering into employment with Pacific Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

The options have an exercise price of $20.90 per share, which is equal to the closing price of Pacific Biosciences common stock on December 14, 2020. The shares subject to the option shall be scheduled to vest and become exercisable as to 1/4th of the total number of shares subject at grant to the Option on the one (1) year anniversary of the Effective Date and as to 1/48th of the total shares subject at grant to the Option each month thereafter on the same day of the month as the Effective Date (or the last day of the month, if a particular month does not have a corresponding day). The RSUs shall be scheduled to vest as to 1/4th of the total number of shares subject at grant to the RSUs on each of the one (1), two (2), three (3), and four (4) year anniversaries of the Effective Date. The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Equity Incentive Plan and the award agreements entered into with the non-executive officer employee.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

Contact

Investors: Trevin Rard
650.521.8450
[email protected]



CONX Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on December 21, 2020

PR Newswire

LITTLETON, Colo., Dec. 18, 2020 /PRNewswire/ — CONX Corp. (Nasdaq: CONXU) (“CONX” or the “Company”) announced that holders of the units sold in the Company’s initial public offering of 75,000,000 units completed on November 3, 2020 (the “offering”) may elect to separately trade the shares of Class A common stock and warrants included in the units commencing on December 21, 2020. Any units not separated will continue to trade on The Nasdaq Capital Market under the symbol “CONXU”, and each of the shares of Class A common stock and warrants will separately trade on The Nasdaq Capital Market under the symbols “CONX” and “CONXW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their broker contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction. The offering was made only by means of a prospectus, copies of which may be obtained on the U.S. Securities and Exchange Commission website at http://www.sec.gov. Alternatively, copies of the prospectus may be obtained from Deutsche Bank Securities, 60 Wall Street, New York, NY 10005, Attn: Prospectus Group, telephone: 800-503-4611, or by emailing [email protected].

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the search for an initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of CONX, including those set forth in the Risk Factors section of the Company’s registration statement for CONX’s initial public offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. CONX undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

 

 

 

Cision View original content:http://www.prnewswire.com/news-releases/conx-corp-announces-the-separate-trading-of-its-class-a-common-stock-and-warrants-commencing-on-december-21-2020-301196236.html

SOURCE Conx Corp.

Bluevine Capital Chooses Medallia For Experience Management

Bluevine Capital Chooses Medallia For Experience Management

SAN FRANCISCO–(BUSINESS WIRE)–Medallia, Inc. (NYSE: MDLA), the global leader in experience management, today announced that Bluevine Capital has selected Medallia as its experience management platform of choice.

“It is very exciting to see an innovative, small-business-focused fintech leveraging Medallia’s technology to deliver exceptional experience to their thousands of digitally-focused business owners,” said Elizabeth Carducci, chief revenue officer for Medallia.

Follow us on LinkedIn, Twitter, Facebook and Instagram

About Medallia

Medallia (NYSE: MDLA) is the pioneer and market leader in Experience Management. Medallia’s award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens. Medallia captures experience signals created on daily journeys in person, on calls and digital channels, over video and social media and IoT interactions and applies proprietary AI technology to reveal personalized and predictive insights that can drive action with tremendous business results. Using Medallia Experience Cloud, customers can reduce churn, turn detractors into promoters and buyers, create in-the-moment cross-sell and up-sell opportunities and drive revenue-impacting business decisions, providing clear and potent returns on investment. www.medallia.com

© 2020 Medallia, Inc. All rights reserved. Medallia®, the Medallia logo, and the names and marks associated with Medallia’s products are trademarks of Medallia. All other trademarks are the property of their respective owners.

PR Contact:

Valerie Beaudett

[email protected]

+1 (650) 400-7833

IR Contact:

Carolyn Bass

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Technology Internet Data Management

MEDIA:

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass.–(BUSINESS WIRE)–
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 233,500 shares of Kala Pharmaceuticals common stock to forty-six new employees. The stock options were granted on December 15, 2020. The grants were approved by the Compensation Committee and were made as an inducement material to each employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $7.63 per share, the closing price of Kala Pharmaceuticals’ common stock on December 15, 2020. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. Vesting of each option is subject to such employee’s continued service with Kala Pharmaceuticals through the applicable vesting dates.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the October 2020 approval of EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.

Investor Contacts:

Loraine Spreen

[email protected]

857-277-4842

Hannah Deresiewicz

[email protected]

212-362-1200

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Health Surgery Clinical Trials Pharmaceutical Optical Biotechnology

MEDIA:

Eargo Ranks First for Best Company Culture in Comparably Awards

Eargo is also named to “Best Company for Women” and “Best CEOs” list

SAN JOSE, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) — Eargo, Inc. (Nasdaq: EAR) a medical device company on a mission to improve the quality of life for people with hearing loss, announced today that it has won the Comparably Award for “Best Company Culture” in the small business category. Eargo was also named a “Best Company for Women,” and CEO Christian Gormsen was named to the “Best CEO” list for the second time in three years.

The recognition caps another strong year for Eargo in the Comparably Awards, which includes wins in “Best Company Perks & Benefits,” “Best Company Compensation,” “Best Company Happiness,” “Best CEOs for Women” and “Best CEOs for Diversity,” and underscores its commitment to empowering employees to be bold, nimble and real.

Christian Gormsen, President and Chief Executive Officer, said, “Our team’s resilience and unity throughout 2020 made it the best in our company’s history. I’m proud to see everyone recognized as the gold standard in not only our industry, but across all industries, for what can be achieved together despite unprecedented adversity.”

The complete lists of “Best Company Culture” can be found here, the “Best CEOs” here, and the “Best Company for Women” here.

About Eargo

Eargo is a medical device company dedicated to improving the quality of life of people with hearing loss. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first and only virtually invisible, rechargeable, completely-in-canal, FDA regulated, exempt Class I device for the treatment of hearing loss. Our differentiated, consumer-first solution empowers consumers to take control of their hearing. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.

The company’s 4th generation product, the Eargo Neo HiFi was launched in January and features increased bandwidth, improved feedback cancellation, and a sophisticated wind noise reduction algorithm for enhanced performance processing speech outdoors. The Eargo Neo HiFi is available for purchase here.

Investor Contact

Nick Laudico
Vice President of Investor Relations
[email protected]

Media Contact

Brad Sheets
[email protected]



BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

PR Newswire

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial public offering of 12,075,000 shares of common stock at a public offering price of $18.00 per share, which includes 1,575,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of the shares of common stock were offered by BioAtla. The shares of common stock began trading on the Nasdaq Global Market on December 16, 2020 under the ticker symbol “BCAB.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by BioAtla, were approximately $217.4 million.

J.P. Morgan, Jefferies and Credit Suisse acted as joint book-running managers for the offering. BTIG acted as co-manager for the offering.

Registration statements relating to these securities became effective on December 15, 2020. Copies of the registration statements can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov. The securities referred to in this release were offered only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388, or by email at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioAtla
BioAtla is a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

Media Contact:

Richard A. Waldron, CFO
BioAtla, Inc.
[email protected] 

Investor Contact:

Richard A. Waldron, CFO
BioAtla, Inc.
[email protected] 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bioatla-announces-closing-of-initial-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-301196233.html

SOURCE BioAtla, Inc.

Nanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs

Nanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the closing of an additional 1,095,000 American Depositary Shares (“ADSs”) pursuant to the full exercise of the underwriters’ option to purchase additional ADSs in connection with the Company’s initial public offering on the Nasdaq Global Select Market.

The 1,095,000 additional ADSs were sold at $13.50 per ADS, the same public offering price as in the initial public offering. Consequently, the total number of ordinary shares issued amounts to 8,395,000, including 6,540,000 in the form of ADSs, and the total net proceeds (including the sale of the additional ADSs pursuant to the exercise of the underwriters’ option), after deducting underwriting commissions and estimated offering expenses payable by Nanobiotix, from the initial public offering were approximately $100.4 million (€82.8 million)1. The Company believes that the total net proceeds, together with its cash and cash equivalents, will be sufficient to fund its operations through the middle of the second quarter of 2023.

Nanobiotix’s ordinary shares are listed on the regulated market of Euronext in Paris under the ticker symbol “NANO”. Nanobiotix’s ADSs began trading on the Nasdaq Global Select Market on December 11, 2020 under the ticker symbol “NBTX”.

Jefferies LLC acted as global coordinator and joint book-running manager for the global offering, and Evercore Group, L.L.C. and UBS Securities LLC acted as joint book-running managers for the U.S. offering. Gilbert Dupont acted as manager for the European offering.

The initial public offering was made only by means of a prospectus. A copy of the prospectus relating to the initial public offering was filed with the U.S. Securities and Exchange Commission and may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at [email protected]; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at [email protected]; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at [email protected].

Allocation of the Share Capital

The following table presents the expected allocation of the Company’s share capital following the initial public offering, to the Company’s knowledge:

 

Situation before the capital increase (on a

non-diluted basis)

Situation after the capital increase (on a non-

diluted basis and including the exercise of

the underwriters’ option to purchase

additional ADSs )

Shareholders

Number of

shares

% of share

capital

% of voting

rights

Number of

shares(1)

% of share

capital

% of voting

rights

Institutional Investors

8,428,377

32.37%

31.17%

11,509,459

33.43%

32.48%

Amiral Gestion

1,418,179

5.45%

5.25%

1,479,619

4.30%

4.18%

Baillie Gifford

409,836

1.57%

1.52%

2,109,836

6.13%

5.95%

Qatar Holding

0

0%

0%

1,850,000

5.37%

5.22%

Invus

330,000

1.27%

1.22%

2,032,478

5.90%

5.74%

Retail

13,734,003

52.75%

50.80%

13,734,003

39.89%

38.76%

Management

962,613

3.70%

6.06%

962,613

2.80%

4.62%

including Laurent Levy

809,060

3.11%

5.10%

809,060

2.35%

3.90%

Employees (excl.

management)

450,211

1.73%

2.87%

450,211

1.31%

2.19%

Family offices and others

298,388

1.15%

1.10%

298,388

0.87%

0.84%

Liquidity Contract

5,515

0.02%

0.02%

5,515

0.02%

0.02%

Total

26,037,122

100.00%

100.00%

34,432,122

100.00%

100.00%

(1) 6,540,000 of which are ordinary shares represented by ADSs

***

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205 / Bloomberg: NANO: FP) and the Nasdaq Global Select Market (Nasdaq: NBTX). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

1 Based on an exchange rate of €1.00 = $1.2115 as published by the European Central Bank on December 10, 2020.

Nanobiotix

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

[email protected]

Investor Relations Department

Ricky Bhajun (EU)

Senior Manager, Investor Relations

+33 (0)1 79 97 29 99

[email protected]

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0)6 64 79 97 51

[email protected]

US – Porter Novelli

Scott Stachowiak

+1 (212) 601 8000

[email protected]

KEYWORDS: Massachusetts Europe United States North America France

INDUSTRY KEYWORDS: Pharmaceutical Health Oncology Clinical Trials

MEDIA:

Logo
Logo

Lattice Low Power FPGAs Inspire Innovative Development Boards from Open Source Community

Lattice Low Power FPGAs Inspire Innovative Development Boards from Open Source Community

New Webpage Highlights Broad Array of “Community Sourced” Development Boards and Reference Designs

HILLSBORO, Ore.–(BUSINESS WIRE)–Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today announced its new Community Sourced Development Board webpage to highlight the many open source hardware development boards and reference designs developed by innovators in the open source community that use Lattice’s low power, small form factor, highly-reliable FPGAs.

“The open source community is a great resource for problem solving and innovation among developers in the electronics industry,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “We thank open source developers for their interest in exploring the possibilities of our low power Lattice FPGAs and for sharing their creative thinking with the broader community. We continue to be amazed and excited by the breadth and depth of the community’s creativity.”

To see the list of community sourced boards on the Lattice website, or to submit a new open source project that you would like to be considered for posting to the Lattice Community Sourced webpage, please visit: https://www.latticesemi.com/en/Solutions/Solutions/SolutionsDetails01/CommunitySourced.

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo or Youku.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

MEDIA CONTACT:

Bob Nelson

Lattice Semiconductor

408-826-6339

[email protected]

INVESTOR CONTACT:

Rick Muscha

Lattice Semiconductor

408-826-6000

[email protected]

KEYWORDS: United States North America Oregon

INDUSTRY KEYWORDS: Consumer Electronics Technology Semiconductor Telecommunications Nanotechnology Networks Audio/Video Internet Mobile/Wireless Hardware Electronic Design Automation

MEDIA:

Logo
Logo

Stop & Shop’s Investment of $229 Million in Retirement Benefits for Union Associates Ratified by UFCW Local 1500

Investment Will Improve Security of Future Pension Benefits for Union Associates & Reduce Financial Risk for the Company

QUINCY, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) — Today Stop & Shop announced that UFCW Local 1500 has ratified an agreement for the company to make a $229 million investment in pension benefits for its members.

“We’re pleased this agreement has been ratified as it will improve the security of future retirement benefits for our union associates, while reducing financial risk going forward. This represents a significant investment in our associates who are dedicated to serving our communities every day,” said Gordon Reid, President, Stop & Shop.

As part of the agreement, the following actions will occur:

  • Stop & Shop will end its participation in the UFCW Local 1500 Pension Fund.
  • Stop & Shop union associates will participate in the Local 1500 Annuity plan, which is intended to sustainably provide future retirement benefits and reduce financial risk to the company.

The agreement covers approximately 8,000 current Stop & Shop associates who are members of UFCW Local 1500.

About Stop & Shop                

A neighborhood grocer for more than 100 years, today’s Stop & Shop is refreshed, reenergized and inspired, delivering convenient new solutions for customers. Committed to helping its communities enjoy better food and better lives, Stop & Shop has a longstanding history of giving back to the neighborhoods it serves with a focus on fighting hunger and pediatric cancer research and care. The Stop & Shop Supermarket Company LLC is an Ahold Delhaize USA Company and employs nearly 58,000 associates and operates over 400 stores throughout Massachusetts, Connecticut, Rhode Island, New York and New Jersey. To learn more about Stop & Shop, visit stopandshop.com. 

Contact: [email protected]